Triple therapy for advanced @entity5 of the XXXX .

@entity1 @entity135 @entity5 @entity900 @entity1499
Eighty-two @entity1 with advanced @entity5 of the @entity135 have been treated with sequential administration of @entity1499 and @entity900 . @entity1499 was given orally (50 mg/sq m). @entity900 was given intravenously 24 hours later. Treatment was repeated four times at weekly intervals. This method of administration is based on laboratory evidence, including cell kinetic studies. Forty-three @entity1 were operated on. Those with involved or close surgical margins or with more than one cancerous neck node were also treated with therapeutic postoperative radiation therapy. Twenty-two @entity1 were treated with only radiation therapy. After surgery and/or radiation therapy, @entity1 were randomly selected as to who would receive further chemotherapy or who would be under observation only. Twenty-two @entity1 are still in the early phases of treatment and follow-up, so their conditions could not be evaluated. Early results indicate a 64% response to initial chemotherapy and no increase in operative difficulty, morbidity, or mortality.
